Neuroblastoma
Conditions
Brief summary
This research studies chromosomes in samples from younger patients with neuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
Detailed description
OBJECTIVES: I. Determine the impact on overall survival of patients with non-MYCN neuroblastoma below 18 months of age as compared to neuroblastoma patients above 18 months of age. OUTLINE: Archived DNA samples are analyzed for segmental chromosome aberrations by multiplex ligation-dependent probe amplification (MLPA), a polymerase chain reaction (PCR)-based technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and 17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
Interventions
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Samples from neuroblastoma patients who, according to risk stratification, did not receive cytotoxic treatment and did never receive chemotherapy and are in complete response (CR) OR patients who, according to risk stratification, did not receive cytotoxic treatment initially, but had a localized or a systemic (stage Ms or M) relapse with or without following chemotherapy * Low-risk Children Oncology Group (COG) designation: no initial cytotoxic treatment, any stage, any age, any outcome * DNA from untreated neuroblastoma tumor samples (from patients in the age group below and from patients in the age group above 1.5 years of age) available from the COG, Europe, Israel, and Japan * No MYCN amplification * No Schwann cell stroma-rich tumors * No tumor cell content below 60% * No DOT * No patients diagnosed before 1997 and after 2005 * No lack of follow-up data * See Disease Characteristics * No initial cytotoxic treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | From the date of diagnosis to the date of death from any cause, assessed up to 5 years | Estimated by the Kaplan-Meier method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival (EFS) | From the date of diagnosis to the date of disease progression, death from any cause, or secondary neoplasm, assessed up to 5 years | Estimated by the Kaplan-Meier method. |
| Incidence of metastatic relapses using cumulative incidences | Up to 5 years | Grey's test and the model of Fine and Grey will be used for the evaluation of statistical significance. |
Countries
United States
Outcome results
None listed